TPX Related Analyst Ratings
-
Hilliard Lyons Downgrades Tempur-Pedic (TPX) to Long-Term Buy
-
Tigress Financial Partners Starts Tempur-Pedic (TPX) at Strong Buy
-
Oppenheimer Maintains a 'Perform' on Tempur-Pedic (TPX); Those are Fighting Words
-
UBS Cuts Estimates and Price Target on Mattress Firm Holding Corp. (MFRM); Might Need Some Tylenol PM
-
Analyst Sticks His Neck Out, Upgrades Tempur-Pedic (TPX) to Buy Following FY12 Warning
-
Goldman Sachs Chops PT and Estimates on Tempur-Pedic (TPX); From Growth to Value
-
William Blair Downgrades Tempur-Pedic (TPX) to Market Perform
-
Wedbush Downgrades Tempur-Pedic (TPX) to Neutral; Cutting Numbers and Removing From Best Ideas List
-
Piper Jaffray Downgrades Tempur-Pedic (TPX) to Neutral
-
UBS Defends Mattress Firm Holding Corp. (MFRM); A Few Adjustments, But Still The Same Bed
-
KeyBanc Downgrades Tempur-Pedic (TPX); Was Not 'Expecting Anything as Dramatic as Today's Announcement'
-
Barclays Channel Checks Into Holiday Mattress Sales; Competition Stiffens
-
Piper Jaffray Says Strong Mattress Sales in April Good Sign for Select Comfort (SCSS), Tempur-Pedic (TPX) (ZZ)
-
Raymond James Upgrades Tempur-Pedic (TPX) to Strong Buy
-
Oppenheimer Reiterates Buy, Reduces Price Target on Tempur-Pedic (TPX)
-
Piper Jaffray, Oppenheimer Say Buy the Dip in Tempur-Pedic (TPX); Shares Up 7%
-
Barclays Takes More Conservative Tone on Tempur-Pedic (TPX); Cutting Price Target As Competitive Forces Change
-
Tempur Pedic (TPX) Clobbered After Rare Mattress Discount, Short Seller Concerns
-
Standpoint Research Downgrades G-III Apparel (GIII) to Hold; Making Moves in Retail
-
Standpoint Research Upgrades Tempur-Pedic (TPX) to Buy
-
Hilliard Lyons Upgrades Tempur-Pedic (TPX) to Long-Term Buy
-
Stephens Downgrades Tempur-Pedic (TPX) to Equal Weight
-
Goldman Sachs Cuts Price Target on Tempur-Pedic (TPX) After Guidance Not Raised
-
KeyBanc Maintains a 'Buy' on Tempur-Pedic (TPX); Raising Numbers After Positive Channel Checks
-
Wedbush Reiterates an 'Outperform/Best Idea' on Tempur-Pedic (TPX); See Further Upside
-
Oppenheimer Reiterates an 'Outperform' on Tempur-Pedic (TPX); Meeting with Mgmt Confirms Belief
-
Raymond James Downgrades Tempur-Pedic (TPX) to Market Perform
-
Shares of Tempur-Pedic (TPX) Tap New 52-wk High; Barclays Highlights Investor Day
-
KeyBanc Raises Price Target on Tempur-Pedic (TPX) Ahead of Analyst Day on February 22
-
KeyBanc Remains Extremely Bullish on Mattress Firms, Raises Price Targets (MFRM) (TPX) (ZZ) (SCSS)
-
Standpoint Research Starts Medifast (MED) at Buy; This Consumer Staple Has Value
-
Standpoint Research Downgrades Tempur-Pedic (TPX) to Hold; Moving To Sidelines
-
Wall Street Positive on Mattress Firm (MFRM); Don't Sleep on Shares
-
Oppenheimer Upgrades Tempur-Pedic (TPX) to Outperform; Investor Concerns Overstated & Manageable
-
Standpoint Research Upgrades Tempur-Pedic (TPX) to Buy; Attractive Valuation
-
Standpoint Research Upgrades Symantec (SYMC) to Buy; Attractive Valuation
-
Standpoint Research Upgrades Freeport-McMoRan (FCX) to Buy; Valuation Still Attractive
-
Standpoint Research Downgrades Tempur-Pedic (TPX) to Hold
-
Piper Jaffray Assumes Coverage on Tempur-Pedic (TPX) at Overweight, $67 Price Target
-
Standpoint Research Upgrades Tempur-Pedic (TPX) to Buy
-
Goldman Sachs Starts Tempur-Pedic (TPX) at Neutral
-
Standpoint Research Downgrades Tempur-Pedic (TPX) to Hold
-
KeyBanc Lowers Price Target on Tempur-Pedic (TPX), Strong Long-Term Buy
-
Standpoint Research Starts Tempur-Pedic (TPX) at Buy
-
Wedbush Adds Tempur-Pedic (TPX) to its Best Ideas List, Reiterates $80 Price Target
-
Barclays Maintains an 'Equalweight' on Tempur-Pedic (TPX); Raising Numbers on Q2 Results
-
KeyBanc Reiterates a 'Buy' on Tempur-Pedic (TPX); Raising PT & Estimates
-
Canaccord Genuity Morning Coffee on Tempur Pedic (TPX); Not Tempuring its Expectations
-
Barclays Maintains an 'Equalweight' on Tempur-Pedic (TPX); Revising Estimates
-
KeyBanc Raises Price Target, Estimates on Tempur-Pedic (TPX) Following Preliminary Results
Back to TPX Stock Lookup
